SCHEMBL10866675

SCHEMBL10866675

CN(C)CCCN1CCC(C(C(N)=O)(c2ccccc2)c2ccccc2)C1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KCNH2 Q12809 4/20 0.55
▸ CHRM3 P20309 3/20 0.55
▸ CHRM2 P08172 2/20 0.55
▸ ADRB2 P07550 2/20 0.55
▸ HTR2A P28223 2/20 0.55
▸ HTR2B P41595 2/20 0.55
▸ CHRM4 P08173 1/20 0.55
▸ ADRB1 P08588 1/20 0.55
▸ CHRM5 P08912 1/20 0.55
▸ ADRA2A P08913 1/20 0.55
▸ CHRM1 P11229 1/20 0.55
▸ DRD2 P14416 1/20 0.55
▸ KCNE1 P15382 1/20 0.55
▸ ADRA2B P18089 1/20 0.55
▸ ADRA2C P18825 1/20 0.55
▸ HRH2 P25021 1/20 0.55
▸ SLC6A4 P31645 1/20 0.55
▸ ADRA1A P35348 1/20 0.55
▸ OPRM1 P35372 1/20 0.55
▸ OPRK1 P41145 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4356190 0.96 CHRM3 (0.53) KCNH2CHRM3CHRM2ADRB2HTR2A
SCHEMBL4345490 0.96 CHRM3 (0.53) KCNH2CHRM3CHRM2ADRB2HTR2A
SCHEMBL4345499 0.96 CHRM3 (0.53) KCNH2CHRM3CHRM2ADRB2HTR2A
SCHEMBL4356193 0.96 CHRM3 (0.53) KCNH2CHRM3CHRM2ADRB2HTR2A
SCHEMBL10868089 0.93 OPRM1 (0.57) KCNH2CHRM3CHRM2ADRB2HTR2A
SCHEMBL4422712 0.90 CHRM3 (0.53) KCNH2CHRM3CHRM2ADRB2HTR2A
SCHEMBL4422709 0.90 CHRM3 (0.53) KCNH2CHRM3CHRM2ADRB2HTR2A
SCHEMBL13592297 0.88 CHRM3 (0.61) KCNH2CHRM3CHRM2ADRB2HTR2A
SCHEMBL13590293 0.88 CHRM3 (0.61) KCNH2CHRM3CHRM2ADRB2HTR2A
SCHEMBL13590341 0.88 CHRM3 (0.61) KCNH2CHRM3CHRM2ADRB2HTR2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0178946-A2 1-(Aminoalkyl)-alpha, alpha-diaryl pyrrolidine-piperidine- and homopiperidine- acetamides and acetonitriles A.H. ROBINS COMPANY, INCORPORATED (US) 1986-04-23 — — EP claimed
US-20090306134-A1 Muscarinic receptor antagonists THERAVANCE BIOPHARMA R&D IP, LLC 2009-12-10 — — US disclosed
US-7456203-B2 Muscarinic receptor antagonists THERAVANCE, INC. (US) 2008-11-25 — — US disclosed
EP-0178946-A2 1-(Aminoalkyl)-alpha, alpha-diaryl pyrrolidine-piperidine- and homopiperidine- acetamides and acetonitriles A.H. ROBINS COMPANY, INCORPORATED (US) 1986-04-23 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090306134-A1 Muscarinic receptor antagonists CHRM3, CHRM5, CHRM2 KCNH2 1070/4885CHRM3 1/4885CHRM2 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback